Company Analysis
Sign in

Allogene Therapeutics, Inc. (ALLO)

Nasdaq: ALLO · Biological Products, (No Diagnostic Substances) · South San Francisco, CA · filing with the SEC since 2018
Full chart Alerts Compare
Grade3.7
◀ Past 3.1● Present 4.9▶ Future 3.1
4 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart
The companyfiscal 2025, as filed
Revenue$0.00-100.0%
Net income-$191M+25.9%
Earnings per share$-0.87+34.1%
Operating cash flow-$149M+25.5%
Cash$51.7M-31.3%
Debtn/a
Shareholders’ equity$293M-30.7%
Shares, diluted220.6M+13.2%
Return on equity-65.3%
The recordfrom its filings
Filings in 202677
Newest filingNov 10 · SCHEDULE 13G
Annual reportMar 12, 2026
Quarterly reportNov 6, 2026
Next report due10-K by Mar 31
Insider sales, 12 months$700,000
Insider buys, 12 months$0.00
Patents granted18
Filer categoryNon-accelerated filer<br>Smaller reporting company
Trailing twelve months to Sep 2026Net income -$174MCash from operations -$109Mthe four newest filed quarters added
Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.
Revenue and net income by fiscal yearRevenueNet income
1819202122232425
As filed, in USD. Nothing here is a forecast.

News

Nov 10, 2026 · SEC EDGAR · Form SCHEDULE 13G
Large holder notice
Open the filing on sec.gov
Nov 6, 2026 · SEC EDGAR · Form 10-Q
Quarterly report
Open the filing on sec.gov
Nov 5, 2026 · SEC EDGAR · Form 8-K
Results released
Open the filing on sec.gov
Oct 23, 2026 · SEC EDGAR · Form 4
Insider trade report
Open the filing on sec.gov
Sep 2, 2026 · SEC EDGAR · Form 8-K
Current report
Open the filing on sec.gov
Aug 25, 2026 · SEC EDGAR · Form 4
Insider trade report
Open the filing on sec.gov
An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.
SI Assistanton ALLO · research, not advice